重大公告
Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial
Date of occurrence of the event: Jul 27, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Date of occurrence of the event: Jul 7, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
Announcement on the board resolution at Annual General Meeting 2018
Date of the shareholders’ meeting: Jun 27, 2018 Important resolutions (1) profit distribution/deficit compensation: the 2017 earning distribution and expense appropriation was recognized Important resolutions …
Amendment on the announcement for 2018 Annual General Meeting (discussion notes)
Date of the board of directors resolution: May 11, 2018 Date for convening the shareholders’ meeting: June 27, 2018 Location for convening the shareholders’ meeting: …
The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle cash-increase of common shares to issue overseas depository receipts
Date of the board of directors resolution: May 11, 2018 Source of capital increase funds: ash-increase of common shares to issue overseas depository receipts Number …